세계적인 암 유병률 증가와 최소침습적 치료의 기술 발전으로 종양 절제술에 대한 수요가 증가하고 있습니다. 고주파 소작 및 마이크로파 소작과 같은 기술을 사용하는 종양 절제술은 특히 외과적 개입을 받을 수 없는 환자에게 기존 수술에 대한 대안을 제공합니다. 이에 따라 종양 절제술 시장은 2023년 12억 달러 이상의 매출을 달성하고 2031년에는 약 26억 달러 규모에 달할 것으로 예측됩니다.
종양 절제술은 주변 조직에 해를 끼치지 않고 종양 세포를 표적화하여 파괴하는 정확도가 높아 간, 폐, 신장과 같은 장기의 작은 종양을 치료하는 데 선호되고 있습니다. 이 시장은 최소침습적 시술에 대한 수요 증가와 기술 발전으로 인해 2024년부터 2031년까지 연평균 12.9%의 성장률을 나타낼 것으로 예상됩니다.
종양 절제술 시장 정의/개요
종양절제술은 기존의 수술로 종양을 절제하지 않고 암세포를 파괴하기 위해 사용되는 최소침습적 시술을 말합니다. 이 기술은 고주파, 마이크로파, 냉동 절제술 등 다양한 형태의 에너지를 사용하여 암세포를 파괴합니다. 이러한 기술은 특히 나이, 건강 상태, 종양의 위치 등의 이유로 수술이 불가능한 환자들을 대상으로 다양한 유형의 암 치료에 사용되고 있습니다.
종양 절제술은 회복 시간 단축, 합병증 감소, 외래 수술 가능 등의 장점이 있습니다. 간 종양, 폐 종양, 신장 종양, 뼈 종양 치료에 자주 사용됩니다. 개인화된 최소침습적 치료 옵션에 대한 수요가 증가함에 따라 종양 절제술 시장의 미래는 영상 유도 기술의 발전과 면역 요법 및 화학 요법과 같은 다른 치료법과의 통합에 달려 있습니다.
세계적인 암 발병률 증가, 특히 간암, 폐암, 신장암 증가는 종양 절제술 시장의 중요한 촉진요인입니다. 세계보건기구(WHO)에 따르면 2040년까지 암 환자가 47% 증가할 것으로 예상되며, 이는 치료 옵션에 대한 수요 증가로 이어지고 있습니다. 종양 절제술은 최소 침습적이고 수술에 적합하지 않은 환자를 치료할 수 있기 때문에 널리 받아들여지고 있습니다.
또한, 입원 기간과 회복 시간을 단축하는 외래 환자 치료에 대한 선호도가 높아짐에 따라 종양 절제 기술의 채택이 더욱 증가하고 있습니다. 또한, 의료 인프라 개선과 암에 대한 인식이 높아짐에 따라 신흥 시장에서 절제술 기술 채택이 증가하고 있는 것도 시장 성장을 가속할 것으로 예상됩니다.
이러한 장점에도 불구하고, 종양 절제술 시장은 높은 치료 비용과 신흥국 지역의 첨단 기술에 대한 접근성 제한과 같은 문제에 직면해 있습니다. 종양 절제술은 전문 장비와 숙련된 전문가가 필요하기 때문에 저소득 지역에서는 치료비가 비싸고 치료 접근성이 떨어집니다. 이 때문에 의료 시스템이 발달하지 않은 지역에서는 종양 절제술의 도입이 제한되고 있습니다.
또한, 일부 국가에서는 의료 서비스 제공업체와 환자에게 큰 도전이 되고 있는 상환 문제가 있습니다. 절제 장비의 높은 비용과 보험 적용 범위의 불일치가 결합되어 소규모 병원 및 클리닉이 이러한 치료를 제공하는 것을 주저하게 만들고 시장 성장을 둔화시킬 수 있습니다.
The growing prevalence of cancer worldwide, along with technological advancements in minimally invasive treatments, is driving the demand for tumor ablation procedures. Tumor ablation, which uses techniques like radiofrequency and microwave ablation, offers an alternative to traditional surgery, especially for patients unable to undergo surgical interventions. This has enabled the Tumor Ablation Market to exceed a revenue of USD 1.2 Billion in 2023 and is projected to reach a valuation of aroundUSD 2.6 Billion by 2031.
Tumor ablation is recognized for its precision in targeting and destroying tumor cells without harming surrounding tissues, making it a preferred choice for treating small tumors in organs like the liver, lungs, and kidneys. The market is expected to grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031 due to the increasing demand for minimally invasive procedures and technological advancements.
Tumor Ablation Market: Definition/ Overview
Tumor ablation refers to minimally invasive procedures used to destroy cancer cells without removing the tumor through traditional surgery. This technology uses different forms of energy, including radiofrequency, microwave, and cryoablation, to destroy cancer cells. These techniques are increasingly being used to treat various types of cancer, particularly in patients who are poor candidates for surgery due to age, health condition, or the tumor's location.
Tumor ablation offers several benefits including reduced recovery times, fewer complications, and the ability to perform the procedure on an outpatient basis. It is commonly used in treating liver, lung, kidney, and bone tumors. As demand for personalized, minimally invasive treatment options rises, the future of the Tumor Ablation Market lies in further advancements in image-guided procedures and integration with other treatment modalities like immunotherapy and chemotherapy.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The rising global incidence of cancer, particularly liver, lung, and kidney cancers is a significant driver of the Tumor Ablation Market. According to the World Health Organization (WHO), cancer cases are expected to rise by 47% by 2040 leading to an increased demand for treatment options. Tumor ablation due to its minimally invasive nature and ability to treat patients who are not suitable for surgery is gaining widespread acceptance.
Moreover, the growing preference for outpatient procedures which reduce hospital stays and recovery times is further boosting the adoption of tumor ablation techniques. The increased adoption of ablation technologies in emerging markets driven by improved healthcare infrastructure and rising cancer awareness is also anticipated to fuel market growth.
Despite its benefits, the Tumor Ablation Market faces challenges including high treatment costs and limited access to advanced technologies in developing regions. Tumor ablation procedures require specialized equipment and trained professionals which can make these treatments costly and less accessible in low-income areas. This limits the adoption of tumor ablation in regions with less-developed healthcare systems.
Furthermore, reimbursement issues in several countries pose a significant challenge for healthcare providers and patients. The high cost of ablation equipment, combined with inconsistent insurance coverage, may deter smaller hospitals and clinics from offering these treatments, potentially slowing market growth.
Radiofrequency ablation (RFA) remains the most widely used technology in tumor ablation due to its proven efficacy and safety. RFA works by generating heat to destroy cancer cells, and it is particularly effective in treating liver and lung tumors. As it offers precise control over the ablation area minimizing damage to surrounding tissues, it continues to be a preferred method in oncology. Meanwhile, microwave ablation is rapidly gaining popularity due to its ability to create larger ablation zones making it suitable for larger tumors. Cryoablation which involves freezing the tumor cells is also gaining traction, particularly in treating kidney and prostate cancers.
While RFA is expected to remain the primary treatment, new technologies like as microwave ablation (MWA) and cryoablation are gaining interest and may challenge its dominance. MWA has benefits such as quicker treatment periods and the potential to treat larger tumors which may be appealing to both physicians and patients. Similarly, cryoablation is being investigated for its unique capacity to freeze tumors which could offer an alternative for certain patient profiles. As these technologies progress and clinical evidence for their efficacy grows, they may acquire a sizable share of the tumor ablation industry.
Liver cancer is one of the most common cancers treated with tumor ablation, and this trend is expected to continue driving market growth. The rising incidence of liver cancer, particularly in Asia-Pacific and North America is boosting the demand for ablation therapies. Tumor ablation is especially beneficial for patients with early-stage liver cancer who are not eligible for surgery. Furthermore, Lung cancer is another significant application area for tumor ablation, particularly for patients with inoperable or recurrent tumors. As healthcare providers increasingly adopt minimally invasive procedures to reduce recovery times and complications, the use of tumor ablation in lung and kidney cancer treatment is expected to rise during the forecast period.
Furthermore, advances in technology are improving the efficacy and precision of tumor ablation techniques. The development of image-guided procedures such as ultrasound and computed tomography (CT) guidance enables more precise tumor targeting, increasing treatment outcomes. As hospitals and clinics engage in updating their facilities with these new technologies, tumor ablation will become more accessible accelerating market growth. Regulatory approvals and clinical research demonstrating the safety and efficacy of these procedures boost confidence among healthcare practitioners and patients, resulting in higher adoption rates.
The North American Tumor Ablation Market is projected to remain the largest regional market due to the region's advanced healthcare infrastructure and increasing adoption of innovative technologies. The U.S. leads the market driven by high healthcare spending, a large patient population, and the presence of key industry players. The increasing prevalence of liver, lung, and kidney cancers coupled with rising awareness about minimally invasive treatments is further propelling market growth.
Furthermore, favorable reimbursement policies and ongoing research in tumor ablation technologies are supporting the market in North America. The growing use of image-guided ablation techniques, such as MRI and CT scans to improve precision in tumor targeting is expected to drive further adoption of tumor ablation therapies.
The Asia Pacific region is expected to witness the highest growth in the Tumor Ablation Market due to the rising incidence of cancer and increasing healthcare investments. Countries such as China, Japan, and India are seeing a surge in cancer cases, particularly liver and lung cancer, which is fueling the demand for tumor ablation procedures. Moreover, government initiatives to improve healthcare access and the growing availability of advanced medical technologies are boosting market growth.
The growing adoption of ablation procedures in the Asia Pacific region is also driven by the growing demand for minimally invasive treatments and the rising awareness of their benefits among patients and healthcare providers. As healthcare infrastructure in emerging economies continues to improve, the Tumor Ablation Market is expected to expand significantly in this region.
The Tumor Ablation Market is characterized by a mix of established and emerging players, each focusing on technological advancements, strategic partnerships, and product innovations to maintain a competitive edge. Companies are investing in developing new ablation technologies that offer improved precision, safety, and patient outcomes.
Some of the prominent players in the Tumor Ablation Market include:
Boston Scientific Corporation, Medtronic PLC, AngioDynamics, Inc., Merit Medical Systems, Johnson & Johnson (Ethicon), EDAP TMS S.A., IceCure Medical Ltd., RF Medical Co. Ltd., Neuwave Medical, Inc. (Johnson & Johnson).
In June 2023, Boston Scientific launched a next-generation microwave ablation system designed to target larger tumors while minimizing damage to healthy tissues.
In October 2022, Medtronic announced its acquisition of an advanced cryoablation technology company to expand its portfolio in tumor ablation treatments.